159 related articles for article (PubMed ID: 12482568)
1. Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia.
Stulc T; Vrablík M; Kasalová Z; Ceska R; Marinov I
Atherosclerosis; 2003 Jan; 166(1):197-8. PubMed ID: 12482568
[No Abstract] [Full Text] [Related]
2. Is rosuvastatin really a more efficient therapeutic option than atorvastatin?
Soto J; Fernandez de Bobadilla J
Value Health; 2006; 9(4):276-7; author reply 277-9. PubMed ID: 16903999
[No Abstract] [Full Text] [Related]
3. Atorvastatin (Lipitor).
Tucker G
Conn Med; 1998 May; 62(5):283-5. PubMed ID: 9639958
[No Abstract] [Full Text] [Related]
4. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
5. LDL cholesterol goals rapidly achieved at various starting doses of Pfizer's atorvastatin.
Cardiovasc J S Afr; 2004; 15(4):190. PubMed ID: 15322577
[No Abstract] [Full Text] [Related]
6. [Atorvastatin . A new generation of hypolipemic agents?].
Azanza JR; Sádaba B; Quetglas EG
Rev Med Univ Navarra; 1998; 42(1):51-5. PubMed ID: 10420957
[No Abstract] [Full Text] [Related]
7. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.
Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
Atherosclerosis; 2004 Aug; 175(2):287-93. PubMed ID: 15262185
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.
Santini SA; Carrozza C; Lulli P; Zuppi C; CarloTonolo G; Musumeci S
J Atheroscler Thromb; 2003; 10(3):160-4. PubMed ID: 14564085
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin.
Wierzbicki AS
Expert Opin Pharmacother; 2001 May; 2(5):819-30. PubMed ID: 11336625
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
11. Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease.
Claeys MJ; Cosyns B; Hoffer E; Carlier M; Missault L; Cools F; De Meester A; Vermeersch P; Gobin E; Dewit B;
Acta Cardiol; 2004 Jun; 59(3):269-74. PubMed ID: 15255458
[TBL] [Abstract][Full Text] [Related]
12. [Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].
Funatsu T; Kakuta H; Tanaka H; Arai Y; Suzuki K; Miyata K
Nihon Yakurigaku Zasshi; 2001 Jan; 117(1):65-76. PubMed ID: 11233299
[TBL] [Abstract][Full Text] [Related]
13. [Atorvastatin (Lipitor)].
Carpentier Y; Ducobu J; Sternon J
Rev Med Brux; 1999 Oct; 20(5):427-33. PubMed ID: 10582478
[TBL] [Abstract][Full Text] [Related]
14. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
15. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy.
Rosenblat M; Hayek T; Hussein K; Aviram M
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):175-80. PubMed ID: 14592851
[TBL] [Abstract][Full Text] [Related]
16. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation.
Lai WT; Lee KT; Chu CS; Voon WC; Yen HW; Tsai LY; Sheu SH
Int J Cardiol; 2005 Feb; 98(3):459-64. PubMed ID: 15708180
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin: a new agent for hyperlipidemia.
Kupecz D
Nurse Pract; 1997 Nov; 22(11):87-8, 90, 93. PubMed ID: 9403876
[No Abstract] [Full Text] [Related]
18. Pitavastatin: the newest HMG-CoA reductase inhibitor.
Watson KE
Rev Cardiovasc Med; 2010; 11(1):26-32. PubMed ID: 20495513
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
20. Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia.
Ikewaki K; Terao Y; Ozasa H; Nakada Y; Tohyama J; Inoue Y; Yoshimura M
J Atheroscler Thromb; 2009 Mar; 16(1):51-6. PubMed ID: 19261998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
